TRANSITION SERVICES AGREEMENTTransition Services Agreement • July 19th, 2019 • Interpace Diagnostics Group, Inc. • Surgical & medical instruments & apparatus • Delaware
This Transition Services Agreement (this “Agreement”) is made as of the 15th day of July, 2019 (the “Effective Date”), by and between Cancer Genetics, Inc., a Delaware corporation (“CGI”) and Interpace BioPharma, Inc., a Delaware corporation (“Buyer”). Buyer and CGI are sometimes referred to herein collectively, as the “Parties” and individually, each a “Party”.
ContractLoan Agreement • July 19th, 2019 • Interpace Diagnostics Group, Inc. • Surgical & medical instruments & apparatus • Delaware
All amounts (including all principal, interest, and other payments) payable by Maker under this Note are and shall be subordinate and junior in right of payment to the prior payment in full in cash of the indebtedness of Maker in favor of Silicon Valley Bank under that certain Loan and security Agreement dated as of November 13, 2018, as may be amended from time to time, and the termination of all related commitments, TO THE EXTENT PROVIDED IN SECTION 7 hereof.
INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • July 19th, 2019 • Interpace Diagnostics Group, Inc. • Surgical & medical instruments & apparatus • New York
THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is entered into as of July 15, 2019, by and among Interpace Diagnostics Group, Inc., a Delaware corporation (the “Company”), and Ampersand 2018 Limited Partnership, a Delaware limited partnership (the “Investor” and including its successors and assigns, the “Investors”).
SECURED CREDITOR asset PURCHASE AGREEMENT by and among INTERPACE BIOPHARMA, INC. as the Buyer, partners for growth iv, l.p. as the Seller and CANCER GENETICS, INC. And INTERPACE DIAGNOSTICS GROUP, INC. (solely for purposes of the Specified Sections)...Secured Creditor Asset Purchase Agreement • July 19th, 2019 • Interpace Diagnostics Group, Inc. • Surgical & medical instruments & apparatus
This Secured Creditor Asset Purchase Agreement (this “Agreement”) is made as of July 15, 2019, by and among Interpace BioPharma, Inc., a Delaware corporation (the “Buyer”), Partners for Growth IV, L.P., a Delaware limited partnership (the “Seller”), Cancer Genetics, Inc., a Delaware corporation (including any and all BP Subsidiaries, “CGI”) and, solely for purposes of the Specified Sections, Interpace Diagnostics Group, Inc., a Delaware corporation (“IDXG”). Each of the Buyer, the Seller and CGI is a “Party” and collectively, the “Parties”.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 19th, 2019 • Interpace Diagnostics Group, Inc. • Surgical & medical instruments & apparatus • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of July 15, 2019, by and among Interpace Diagnostics Group, Inc., a Delaware corporation (the “Company”), and Ampersand 2018 Limited Partnership, a Delaware limited partnership (including its successors and assigns, a “Purchaser” or the “Purchasers”).
VOTING AGREEMENTVoting Agreement • July 19th, 2019 • Interpace Diagnostics Group, Inc. • Surgical & medical instruments & apparatus • Delaware
This VOTING AGREEMENT (this “Agreement”) is entered into as of July 15, 2019 by and among Ampersand 2018 Limited Partnership, a Delaware limited partnership (including its successors and assigns, “Purchaser”) and [●], an individual (“Stockholder”).
